Why Johnson & Johnson's Covid-19 vaccine is generating a lot of interest Initial reports indicate the vaccine elicits a very good response. The single-dose vaccine can prove to be a gamechanger, especially in a country with a large population, such as India, where two doses will consume tremendous resources January 18, 2021 / 05:11 PM IST With Johnson & Johnson (J&J)'s COVID-19 vaccine Phase-3 clinical trial data expected to be announced before the end of January, followed by an application for Emergency Use Authorization in the US and other countries, another vaccine may soon become av...